MedTrace Logo

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

NCT06868199 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-09-12

No results posted yet for this study

Summary

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours.

For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.

Conditions

  • Advanced Solid Tumours

Interventions

DRUG

LM-168

Q3W,Intravenous Drip

DRUG

Toripalimab

Q3W,Intravenous

Sponsors & Collaborators

  • LaNova Medicines Limited

    lead INDUSTRY

Principal Investigators

  • Sherry Qin · LaNova Medicines Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-06
Primary Completion
2027-08-01
Completion
2028-02-01
FDA Drug
Yes

Countries

  • Australia
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06868199 on ClinicalTrials.gov